Читать книгу Nanobiotechnology in Diagnosis, Drug Delivery and Treatment - Группа авторов - Страница 4

1 Chapter 1Figure 1.1 Schematic illustration of various inorganic nanomaterials.Figure 1.2 Schematic representation of various organic nanomaterials.Figure 1.3 Role of nanotechnology and nanomaterials in diagnostics and its a...Figure 1.4 Schematic representation of the operating principle of the biosen...Figure 1.5 A general scheme of similar colorimetric nanosensors.Figure 1.6 Schematic representation of comparison between untargeted and tar...

2 Chapter 2Figure 2.1 Nanocomposite of elemental selenium and arabinogalactan, fluoresc...Figure 2.2 The emission spectra of the nanocomposite elemental selenium and ...Figure 2.3 The nuclei of Ehrlich's carcinoma cells after exposure to nanocom...Figure 2.4 Ehrlich's carcinoma cells after exposure to nanocomposite element...Figure 2.5 Regenerative process during fracture (a) The control group. Bone ...Figure 2.6 The effect of the nanocomposite of elemental selenium and arabino...

3 Chapter 3Figure 3.1 Nanoliposome as a carrier for drug delivery.Figure 3.2 Chitosan nanoparticles loaded with drugs.Figure 3.3 Mechanism of Helicobacter pylori inactivation in epithelium cells...

4 Chapter 4Figure 4.1 (a) Photograph and thermal image of a mouse exposed to ACMF for 2...Figure 4.2 Gold‐based nanotheranostic agents. (a) Schematic illustration of ...Figure 4.3 Nanotheranostics against Alzheimer's. (a) Fluorescence imaging of...Figure 4.4 QD‐Apt(Dox) Bi‐FRET system as novel theranostic agent against can...Figure 4.5 Schemes for the generation of reactive oxygen species, EPR effect...Figure 4.6 Polymeric nanoparticles against teratocarcinoma: (a) Dendritic co...Figure 4.7 In vivo photothermal therapeutic evaluation using silica‐based th...Figure 4.8 Synthesis and application of UCMSNs in imaging. (a) Schematic ill...Figure 4.9 Characterization of LPSiNPs and their applications in imaging. (a...Figure 4.10 TEM images of SPIO@Lac‐Gly (a, b) and CNT‐PDDA‐SPIO@Lac‐Gly (c, ...Figure 4.11 Graphene‐encapsulated particles in biomedical applications (ii)....

5 Chapter 5Figure 5.1 Schematic description of Epi‐loaded‐NAS‐24‐functionalized PEI‐PEG...Figure 5.2 Schematic representation of the MUC1 aptamer‐modified PLGA‐Epi‐Pβ...Figure 5.3 Schematic illustration of the polyvalent aptamer‐based structure ...Figure 5.4 Schematic illustration of Apts‐Dendrimer (G3)‐Epi complex formati...

6 Chapter 6Figure 6.1 Schematic representation of possible mechanisms for the penetrati...

7 Chapter 7Figure 7.1 Schematic representation of surfactant‐coated and CHD‐conjugated ...Figure 7.2 Schematic representation of SPIONs and CHD co‐encapsulated polyme...Figure 7.3 Schematic representation of hydrophobic/hydrophilic chemotherapeu...Figure 7.4 Schematic representation of the magneto‐niosomes co‐encapsulating...Figure 7.5 (a) Schematic representation of as‐developed poly(D,L‐lactide‐co‐...Figure 7.6 Schematic illustration of the synthesis of magnetic nanogel co‐en...Figure 7.7 Schematic illustration of preparation of a magneto‐/pH‐responsive...Figure 7.8 Schematic representation of (a) the encapsulation of curcumin int...Figure 7.9 Schematic representation of SPIONs and paclitaxel loaded PLGA‐bas...Figure 7.10 (a) Drug release behaviors of thermoresponsive core/shell magnet...Figure 7.11 (a) SEM/TEM (inserted) image of using poly (lactic acid) (PLA)/m...Figure 7.12 (A) Schematic representation of (a) synthesis of PLGA‐PEG‐T7 pol...

8 Chapter 8Figure 8.1 (a) Toluidine blue O stained tumor samples; (b) Hematoxylin and E...Figure 8.2 Schematic representation of formation of bacteriophage MS2 capsid...Figure 8.3 Three different structures of nanocarriers composed of bacterioph...Figure 8.4 Schematic illustration of self‐assembling tHBcAg dimer consisting...Figure 8.5 (a) An SDS‐polyacrylamide gel of the tHBcAg nanoparticles cross‐l...Figure 8.6 Schematic representation of the Add‐and‐Display method for immobi...

9 Chapter 9Figure 9.1 (a) Typical hysteresis loop of a ferri/ferromagnetic material. (b...Figure 9.2 Schematic illustration of the chemical synthesis approaches descr...Figure 9.3 Schematic demonstration of various grafting approaches of polymer...Figure 9.4 Schematic demonstration of used immobilization methods for polyzw...Figure 9.5 Magnetic targeting. No accumulation of MNPs occurs in the magneti...Figure 9.6 The mechanism of hyperthermia treatment by using MNPs.

10 Chapter 10Figure 10.1 Schematic representation of extraction of chitosan from crustace...

11 Chapter 11Figure 11.1 Schematic representation of the mechanism for the biosynthesis o...Figure 11.2 Diagrammatic illustration of the possible mechanism involved in ...

12 Chapter 12Figure 12.1 TEM micrographs of: (a) nanoparticles adhered to silica filler d...Figure 12.2 Active fungal growth on coatings: (a) Chaetomium globosum (KU936...

13 Chapter 13Figure 13.1 Schematic representation of metallic nanoparticles as a drug del...Figure 13.2 Schematic representation of a liposome as a drug delivery system...Figure 13.3 Schematic representation of a polymeric nanoparticle as a drug d...

14 Chapter 14Figure 14.1 (a) UV‐Visible spectrum analysis of ChBio‐AgNPs conjugate showin...Figure 14.2 TEM micrographs of ChBio‐AgNPs showing (a) particles inside the ...Figure 14.3 (a) SEM micrographs of ChBio‐AgNPs showing well dispersed spheri...Figure 14.4 (a) AFM topology of ChBio‐AgNPs showing well distributed particl...Figure 14.5 TEM analysis of antibacterial activity of ChBio‐AgNPs conjugates...Figure 14.6 TEM analysis of antifungal activity of ChBio‐AgNPs conjugates. (...

15 Chapter 15Figure 15.1 Clinical manifestations of leishmaniases including (a) cutaneous...Figure 15.2 Worldwide endemicity of (a) cutaneous and (b) visceral leishmani...Figure 15.3 Life cycle of Leishmania.Figure 15.4 The way that a drug must pass to access intracellular leishmania...Figure 15.5 Preferential biodistribution of AmB over time in liver and splee...Figure 15.6 Lesion average diameter (mean ± SD) in chronically infected mice...Figure 15.7 (a) Lesion size change in Leishmania major‐infected Balb/c mice ...Figure 15.8 Cytotoxicity of dextran‐AmB bioconjugates against Leishmania....Figure 15.9 Sb concentration in the serum of Swiss mice 3h after oral admini...Figure 15.10 (a) Cellular uptake of AmB and muramyl dipeptide (MdP) conjugat...Figure 15.11 (a) Schematic representation of ultradeformable liposomes (UDL)...Figure 15.12 (a) Differential pattern of IL‐10, TGF‐b, IL‐4 cytokines after ...Figure 15.13 Cytotoxicity of free DETC and DETC‐Beeswax‐OC nanoparticles....Figure 15.14 Effect of copaiba (nanocopa) and andiroba (nanoandi) releasing ...Figure 15.15 (a) Inhibition percentage of intracellular amastigotes in the p...

16 Chapter 17Figure 17.1 The schematic illustration of different factors affecting the to...Figure 17.2 The schematic representation of different nanomaterials having t...